First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors

Trial Profile

First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs HS 10241 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Atridia; Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 13 Jul 2016 Planned number of patients changed from 27 to 36.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top